ONC vs. PLI, ABCN, EMC, FRX, BCT, IPA, MDNA, SCYB, COM, and NVH
Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Medicenna Therapeutics (MDNA), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). These companies are all part of the "biotechnology" industry.
Oncolytics Biotech (TSE:ONC) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.
ProMetic Life Sciences' return on equity of 0.00% beat Oncolytics Biotech's return on equity.
ProMetic Life Sciences received 246 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. However, 75.38% of users gave Oncolytics Biotech an outperform vote while only 67.69% of users gave ProMetic Life Sciences an outperform vote.
Oncolytics Biotech has higher earnings, but lower revenue than ProMetic Life Sciences. Oncolytics Biotech is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncolytics Biotech had 3 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 3 mentions for Oncolytics Biotech and 0 mentions for ProMetic Life Sciences. Oncolytics Biotech's average media sentiment score of 0.28 beat ProMetic Life Sciences' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the media.
Oncolytics Biotech presently has a consensus target price of C$3.00, suggesting a potential upside of 108.33%.
1.9% of Oncolytics Biotech shares are owned by institutional investors. 3.9% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Oncolytics Biotech beats ProMetic Life Sciences on 8 of the 13 factors compared between the two stocks.
Get Oncolytics Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncolytics Biotech Competitors List
Related Companies and Tools
Free ONC Stock Alerts